Our Mission
To improve the quality of genetic research and human healthcare by enabling cost-effective complete sequencing of relevant genes.
Cergentis to advance TLA-based targeted complete next generation sequencing for cancer companion diagnostics.
Uniquely, TLA enables targeted, complete, cost-effective Next Generation Sequencing
Cergentis provides services and kits for targeted NGS sequencing of any (trans)gene of interest
"Unknown translocation partners that drive expression of oncogenes as consequence of cryptic or previous unidentified chromosomal rearrangements were identified in T-cell leukemia patients using Targeted Locus Amplification.”
Princess Máxima Center for Pediatric Oncology
Dr. Jules Meijerink - Principal Investigator (Utrecht, The Netherlands)
"Unlike other targeted sequencing methods, TLA works without detailed prior locus information, as one primer pair is sufficient to amplify and sequence tens to hundreds of kilobases of surrounding DNA.”
Pacific Biosciences
"TLA outperforms traditional methods used in CHO cell-line characterisation and provides higher resolution and sensitivity.”
Synthon
Dr. Stefanie Bartels - Project Leader - Cell Line Development (The Netherlands)
"Thank you so much. Data about the structural changes in our patient are very clear. Really powerful technology!”
University of Turin
Prof. Dr. Alfredo Brusco - Department of Medical Sciences (Italy)
"TLA is a highly efficient method for mapping the insertion site of any transgene.”
Genentech
Dr. Søren Warming - Associate Director/Senior Scientist (San Francisco, CA, USA)
"The main advantage of TLA over conventional approaches is that it generates complete sequence information of a region of interest."
Taconic
"We conclude that TLA is an effective method for the reliable detection of sequence mutations and structural variations that are relevant for disease prognosis in pediatric leukemia.”
Princess Máxima Center for Pediatric Oncology
Dr. Roland Kuiper - Senior PI (Utrecht, The Netherlands)
"Targeted Locus Amplification enables fast identification of new chromosomal rearrangements and genomic breakpoint sequences in human T-ALL and unraveled a higher complexity of chromosomal translocations of known T-ALL oncogenes as thus far appreciated.”
Ghent University
Prof. Dr. Pieter van Vlierberghe - Center for Medical Genetics (Belgium)
"TLA analysis has proven to be very useful to quality control genetically engineered cell lines”
AstraZeneca
Dr. John Wiseman - Associate Director (Molndal, Sweden)
"Cergentis quickly determined transgene insertion for three out of three lines along with providing information on deletions and rearrangements in chromosomal DNA at the site. The service was quick, accurate and reasonably priced, and reports were complete and helpful.”
Harvard University
Prof. Dr. Joshua Sanes - Department of Molecular and Cellular Biology (Cambridge, MA, USA)
"Targeted Locus Amplification (TLA), a comprehensive method of selectively amplifying genes and detecting all variation within, while preserving haplotype information.”
Illumina
"TLA has proven to be a powerful technology for transgene integration site sequencing and for evaluation of structural changes in the transgene and/or integration site.”
Ludwig Maximilians University Munich
Dr. Nik Klymiuk - Molecular Animal Breeding and Biotechnology (Germany)
To improve the quality of genetic research and human healthcare by enabling cost-effective complete sequencing of relevant genes.